Combined Evaluation of HSV Genome and Antibodies in Breast Cancer
Archives of Clinical Infectious Diseases · 2022
DOI: 10.5812/archcid-116780 ↗Kurz gefasst
Fachartikel in der Zeitschrift Archives of Clinical Infectious Diseases, 2022. Verfasst von Zahra Tahmasebi Fard und 2 weiteren Autor:innen. Die Arbeit nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background
Breast cancer develops due to the combination of external and internal risk factors. Also, the role of viruses is considerable in developing breast cancer.
Objectives
This study compared the frequency of herpes simplex virus types 1 and 2 (HSV-1 and HSV-2) and the level of IgM and IgG antibodies against HSV between cancer patients and healthy individuals.
Methods
Sixty women with breast cancer and 60 healthy women (40 with fibroadenoma and 20 in good health) were selected. Breast tissue and serum samples were taken from all the subjects to evaluate the HSV-1 and HSV-2 genome frequency using real-time PCR. Also, serum levels of IgM HSV and IgG HSV antibodies were assessed using the ELISA technique.
Results
The HSV-1 genome was detected in six cancer specimens and in two fibroadenoma specimens (P = 0.143, OR: 3.22, CI95%: 0.623 - 16.66). Three cancer cases and one fibroadenoma case were positive for HSV-2 (P = 0.309, OR: 3.105, CI95%: 0.314 - 30.73). HSV IgM antibody was positive in three subjects in the control group and six in the case group (P = 0.298, OR: 2.11, CI95%: 0.503 - 8.87). Although the higher mean levels of antibodies were found in the case group (4.01 ± 5.91 U/mL) compared to the control group (2.95 ± 3.51 U/mL), there was no statistically significant difference between them (P = 0.179). The serum of all samples was positive for the HSV IgG antibody, and there was a statistically significant difference in its mean levels between the case (91.22 ± 13.58 U/mL) and control (81.58 ± 17.02 U/mL) groups (P = 0.008).
Conclusions
The present study showed that HSV-1 and HSV-2 were not directly related to breast tissue carcinogenesis and may act as co-factors.
Zitieren
APA
Fard, Z. T., Khayamzadeh, M., & Mahdavi, Z. (2022). Combined Evaluation of HSV Genome and Antibodies in Breast Cancer. Archives of Clinical Infectious Diseases. https://doi.org/10.5812/archcid-116780
Vancouver
Fard ZT, Khayamzadeh M, Mahdavi Z. Combined Evaluation of HSV Genome and Antibodies in Breast Cancer. Archives of Clinical Infectious Diseases. 2022. doi:10.5812/archcid-116780
BibTeX
@article{Fard2022,
author = {Fard, Zahra Tahmasebi and Khayamzadeh, Maryam and Mahdavi, Zahra},
title = {Combined Evaluation of HSV Genome and Antibodies in Breast Cancer},
journal = {Archives of Clinical Infectious Diseases},
year = {2022},
doi = {10.5812/archcid-116780}
}
EUVIMED